<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2801210480
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALUNBRIG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BRIGATINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        180
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19586.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Penn Pharmaceutical Services Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Penn Pharmaceutical Services Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            TAKEDA PHARMA A/S
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE43
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alunbrig contains the active substance brigatinib, a type of cancer medicine called a kinase inhibitor. Alunbrig is used to treat adults with advanced stages of a <strong>lung cancer</strong> called non‑small cell lung cancer. It is given to patients whose lung cancer is related to an abnormal form of a gene called anaplastic lymphoma kinase (<em>ALK</em>).</p><p>&nbsp;</p><p><strong>How Alunbrig works</strong></p><p>&nbsp;</p><p>The abnormal gene produces a protein known as a kinase that stimulates the growth of the cancer cells. Alunbrig blocks the action of this protein and thus slows down the growth and spread of the cancer.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Alunbrig:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic </strong>to brigatinib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor before taking Alunbrig or during treatment if you have:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>lung or breathing problems</strong></p><p>Lung problems, some severe, are more frequent within the first 7&nbsp;days of treatment. Symptoms may be similar to symptoms from lung cancer. Tell your doctor of any new or worsening symptoms including breathing discomfort, shortness of breath, chest pain, cough and fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>high blood pressure</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>a slow heartbeat (bradycardia)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>vision disturbance</strong></p><p>Inform your doctor of any visual disturbance that occurs during treatment, such as seeing flashes of light, blurry vision or light hurting your eyes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>muscle problems</strong></p><p>Report any unexplained muscle pain, tenderness or weakness to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pancreas problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>liver problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>high blood sugar</strong></p><p>&nbsp;</p><p>Tell your doctor if you have kidney problems or you are on dialysis.</p><p>&nbsp;</p><p>Your doctor may need to adjust your treatment or stop Alunbrig temporarily or permanently. See also the beginning of section&nbsp;4.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>Alunbrig has not been studied in children or adolescents. Treatment with Alunbrig is not recommended in persons under 18 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Alunbrig</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>The following medicines can affect or be affected by Alunbrig:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ketoconazole, itraconazole, voriconazole:</strong> medicines to treat fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>indinavir, nelfinavir, ritonavir, saquinavir:</strong> medicines to treat HIV infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>clarithromycin, telithromycin, troleandomycin:</strong> medicines to treat bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>mibefradil:</strong> a medicine to treat irregular heart rhythm and high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>nefazodone:</strong> a medicine to treat depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St. John&rsquo;s wort:</strong> a herbal product used to treat depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>carbamazepine:</strong> a medicine to treat epilepsy, euphoric/depressive episodes and certain pain conditions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>phenobarbital, phenytoin:</strong> medicines to treat epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifabutin, rifampicin:</strong> medicines to treat tuberculosis or certain other infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>digoxin:</strong> a medicine to treat heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>dabigatran:</strong> a medicine to inhibit blood clotting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>colchicine:</strong> a medicine to treat gout attacks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pravastatin, rosuvastatin:</strong> medicines to lower elevated cholesterol levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>methotrexate:</strong> a medicine to treat severe joint inflammation, cancer and the skin disease psoriasis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>sulfasalazine: </strong>a medicine to treat severe bowel and rheumatic joint inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>efavirenz</strong>, <strong>etravirine:</strong> medicines to treat HIV infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>modafinil:</strong> a medicine to treat narcolepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>bosentan:</strong> a medicine to treat pulmonary hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>nafcillin:</strong> a medicine to treat bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>alfentanil, fentanyl:</strong> medicines to treat pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>quinidine:</strong> a medicine to treat irregular heart rhythm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cyclosporine, sirolimus, tacrolimus:</strong> medicines to suppress the immune system</p><p>&nbsp;</p><p><strong>Alunbrig with food and drink</strong></p><p><strong>&nbsp;</strong></p><p>Avoid any grapefruit products during treatment as they may change the amount of brigatinib in your body.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>&nbsp;</p><p>Alunbrig is <strong>not recommended</strong> during pregnancy unless the benefit outweighs the risk to the baby. If you are pregnant or think you may be pregnant or are planning to have a baby, talk to your doctor to discuss the risks of taking Alunbrig during pregnancy.</p><p>&nbsp;</p><p>Women of childbearing age being treated with Alunbrig should avoid becoming pregnant. Effective non‑hormonal contraception must be used during treatment and for 4&nbsp;months after stopping Alunbrig. Ask your doctor about the birth control methods that may be right for you.</p><p>&nbsp;</p><p><strong>Breast‑feeding</strong></p><p><strong>&nbsp;</strong></p><p><strong>Do not breast‑feed</strong> during treatment with Alunbrig. It is unknown if brigatinib passes into breast milk and could potentially harm the baby.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p><strong>&nbsp;</strong></p><p>Men receiving treatment with Alunbrig are advised not to father a child during treatment and to use effective contraception during treatment and for 3 months after stopping.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>Alunbrig may cause visual disturbances, dizziness or tiredness. Do not drive or use machines during treatment if such signs occur.</p><p>&nbsp;</p><p><strong>Alunbrig contains lactose</strong></p><p>&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>The recommended dose is</strong></p><p>&nbsp;</p><p>One 90&nbsp;mg tablet once daily for the first 7&nbsp;treatment&nbsp;days; thereafter, one 180&nbsp;mg tablet once daily.</p><p>Do not change the dose without talking to your doctor. Your doctor may adjust your dose according to your needs and this may require use of a 30&nbsp;mg tablet to achieve the new recommended dose.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Treatment initiation pack </strong></p><p>&nbsp;</p><p>At the beginning of your treatment with Alunbrig your doctor may prescribe a treatment initiation pack.</p><p><strong>Method of use</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Alunbrig once daily at the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets whole, with a glass of water. Do not crush or dissolve the tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets can be taken with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you vomit after taking Alunbrig, do not take any more tablets until your next scheduled dose.</p><p>&nbsp;</p><p>Do not swallow the desiccant canister contained in the bottle.</p><p>&nbsp;</p><p><strong>If you take more Alunbrig than you should</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist right away if you have taken more tablets than recommended.</p><p>&nbsp;</p><p><strong>If you forget to take Alunbrig</strong></p><p>&nbsp;</p><p>Do not take a double dose to make up for a forgotten dose. Take your next dose at your regular time.</p><p>&nbsp;</p><p><strong>If you stop taking Alunbrig</strong></p><p><strong>&nbsp;</strong></p><p>Do not stop taking Alunbrig before talking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist immediately</strong> if you have any of the following serious side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>high blood pressure</strong></p><p>Tell your doctor if you get headaches, dizziness, blurred vision, chest pain or shortness of breath.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>vision problems</strong></p><p>Tell your doctor if you experience any visual disturbances, such as seeing flashes of light, blurry vision or light hurting eyes. Your doctor may stop Alunbrig treatment and refer you to an ophthalmologist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>increased blood level of creatine phosphokinase in tests</strong> &ndash; may indicate muscle damage, such as of the heart. Tell your doctor if you have any unexplained muscle pain, tenderness or weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>increased blood levels of amylase or lipase in tests</strong> &ndash; may indicate inflammation of the pancreas</p><p>Tell your doctor if you have upper abdominal pain, including abdominal pain that gets worse with eating and may spread to the back, weight loss or nausea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>increased blood levels of liver enzymes (aspartate aminotransferase, alanine aminotransferase) in tests</strong> ‑may indicate liver cell damage. Tell your doctor if you have pain on the right side of your stomach area, yellowing of your skin or the whites of your eyes, or dark urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>increased blood sugar</strong></p><p>Tell your doctor if you are feeling very thirsty, need to urinate more than usual, feeling very hungry, sick to your stomach, weak or tired, or confused.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>lung inflammation</strong></p><p>Tell your doctor if you have any new or worsening lung or breathing problems, including chest pain, cough, and fever, especially within the first week of taking Alunbrig, as they may be a sign of serious lung problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>slow heartbeat</strong></p><p>Tell your doctor if you have chest pain or discomfort, changes in heartbeat, dizziness, light‑headedness or fainting.</p><p>See also section&nbsp;2, &ldquo;Warnings and precautions&rdquo;.</p><p>&nbsp;</p><p><strong>Other possible side effects are:</strong></p><p>Tell your doctor or pharmacist if you notice any of the following side effects</p><p>&nbsp;</p><p><strong>Very common </strong>(may<strong> </strong>affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cold‑like symptoms (upper respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced number of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced number of white blood cells, called neutrophils and lymphocytes, in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood clotting time shown by test of activated partial thromboplastin time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low platelet counts in blood tests, which may increase the risk of bleeding and bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of insulin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced blood level of phosphorus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced blood level of potassium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced blood level of magnesium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced blood level of sodium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of calcium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms such as numbness, tingling, prickling sensation, weakness or pain in hands or feet (peripheral neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal (belly) pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth and lips (stomatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of the enzyme alkaline phosphatase &ndash; may indicate organ malfunction or injury</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint or muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; musculoskeletal chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of creatinine &ndash; may indicate reduced kidney function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue swelling caused by excess fluid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; memory impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid heartbeat (tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal electrical activity of the heart (prolonged electrocardiogram QT interval)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flatulence</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of lactate dehydrogenase &ndash; may indicate tissue breakdown</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of bilirubin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to sunlight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in arms and legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle and joint stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain and discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100&nbsp;people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of pancreas which may cause severe and persistent stomach pain, with or without nausea and vomiting (pancreatitis)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on either the bottle label or blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Alunbrig contains </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is brigatinib.</p><p>Each 30&nbsp;mg film‑coated tablet contains 30&nbsp;mg brigatinib.</p><p>Each 90&nbsp;mg film‑coated tablet contains 90&nbsp;mg brigatinib.</p><p>Each 180&nbsp;mg film‑coated tablet contains 180&nbsp;mg brigatinib.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other excipients are lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (type A), silica colloidal hydrophobic, magnesium stearate, talc, macrogol, polyvinyl alcohol, and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Alunbrig looks like and contents of the pack
	
	Alunbrig film coated tablets are white to off white, oval (90 mg and 180 mg) or round (30 mg). They are convex on the upper and lower side.
	
	Alunbrig 30 mg: 
•	Each 30 mg tablet contains 30 mg brigatinib. 
•	The film coated tablets are approximately 7 mm in diameter with “U3” on one side and plain on the other side.
	
	Alunbrig 90 mg: 
•	Each 90 mg tablet contains 90 mg brigatinib.
•	The film coated tablets are approximately 15 mm long with “U7” on one side and plain on the other side.

	Alunbrig 180 mg: 
•	Each 180 mg tablet contains 180 mg brigatinib.
•	The film coated tablets are approximately 19 mm long with “U13” on one side and plain on the other side.

	Alunbrig is available in plastic foil strips (blisters) packed in a carton with:
•	Alunbrig 30 mg: 28 film coated tablets
•	Alunbrig 90 mg: 7 or 28 film coated tablets
•	Alunbrig 180 mg: 28 film coated tablets

	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>&nbsp;</p><p>Takeda Pharma A/S</p><p>Dybendal Alle 10</p><p>2630 Taastrup</p><p>Denmark</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>&nbsp;</p><p>Penn Pharmaceutical Services Limited</p><p>Units 23‑24</p><p>Tafarnaubach Industrial Estate</p><p>Gwent</p><p>Tredegar</p><p>NP22 3AA</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Batch Releaser:</strong></p><p>&nbsp;</p><p>Takeda Austria GmbH</p><p>St. Peter‑Strasse 25</p><p>4020 Linz</p><p>Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in Jan 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء ألونبريغ على المادة الفعَّالة بريجاتينيب، وهي نوع من أدوية السرطان تُسمى مُثبطَات الكينيز، ويُستخدَم ألونبريغ لعلاج البالغين ممن يُعانون من سرطان الرئة في مراحل مُتقدِّمَة، ويُسمى سرطان الرئة غير صغير الخلايا. يُعطى هذا الدواء للمرضى ممن يرتبط سرطان الرئة لديهم بشكل غير طبيعي بالجين المُسمى بورم الغدد اليمفاوية الكشمي الكينيزي (ALK).</p><p dir="RTL"><strong>كيف يعمل دواء دواء ألونبريغ</strong></p><p dir="RTL">ينتج الجين الشاذ بروتينًا يُسمى الكينيز الذي يُحفِّز نمو الخلايا السرطانيَّة، ويعمل ألونبريغ على عرقلة عمل هذا البروتين وبالتالي يُثبِّط نمو السرطان وانتشاره.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول دواء ألونبريغ:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك <strong>حساسية</strong> من ألونبريغ أو أي من المكوِّنَات الأخرى لهذا الدواء (المُدْرَجَة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدَّث مع طبيبك قبل أو أثناء العلاج بدواء ألونبريغ إذا كنت تُعاني من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُشكلات في التنفس أو الرئتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث مشكلات في الرئة &ndash; بعضها شديد &ndash; بصورة أكثر تكرارًا خلال السبعة أيام الأولى من العلاج، وقد تكون الأعراض مًشابهة لأعراض سرطان الرئة. أخبر طبيبك عن أي أعراض جديدة أو مُتفاقمة بما في ذلك عدم الارتياح أثناء التنفس، وضيق التنفس، وألم الصدر، والسُعال، والحُمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء نبضات القلب (بطء القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية.</p><p dir="RTL">أخبِر طبيبك بأي اضطراب بصري يحدث أثناء العلاج مثل رؤية ومضات ضوئية، أو رؤية ضبابيَّة، أو ضوء يضر بعينيك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في العضلات.</p><p dir="RTL">أخبِر طبيبك عن أي مشاكل آلام أو ليونة أو ضعف بالعضلات لا يُعرف سببها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم.</p><p dir="RTL">أخبِر طبيبك إذا كنت تعاني من مشكلات في الكليتين أو إذا كنت تخضع لغسيل كُلَوي.</p><p dir="RTL">قد يكون طبيبك بحاجة إلى ضبط علاجك أو إيقاف ألونبريغ بصورة مؤقتة أو دائمة. انظر أيضًا بداية القسم 4.</p><p dir="RTL"><strong>الأطفال والمراهقين:</strong></p><p dir="RTL">لم يُختَبَر دواء ألونبريغ على الأطفال أو المراهقين، ولا يُنصَح بالعلاج باستخدام دواء ألونبريغ في الأشخاص ممن تقل أعمارهم عن 18 عامًا.</p><p dir="RTL"><strong>ألونبريغ</strong><strong> وأدوية أخرى:</strong></p><p dir="RTL">أخبِر طبيبك إذا كنت تأخذ أي أدوية أخرى أو أخذتها مؤخَّرًا أو من المُحتمَل أن تأخذها.</p><p dir="RTL">الأدوية التالية يمكن أن تؤثر أو تتأثر بالألونبريغ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكيتوكونازول، الإيتراكونازول، الفوركونازول: أدوية لعلاج الالتهابات الفطرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإندينافير، النلفينافير، الريتونافير، الاسكوينافير: أدوية لعلاج فيروس العوز المناعي البشري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكلاريثروميسن، اليليثروميسين، الترولياندوميسين: أدوية لعلاج الالتهابات البكتيرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميبيفراديل: دواء لعلاج عدم انتظام ضربات القلب وارتفاع ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النيفازودون: دواء لعالج الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة القديس يوحنا: وهي مُنتَج عُشبي يُستخدم لعلاج الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكاربامازيبين: وهو دواء لعلاج نوبات الصرع والنشوة/الاكتئاب وبعض حالات الألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينوباربيتال، الفينيتوين: أدوية لعلاج الصرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريفابوتين، والريفامبيسين: أدوية لعلاج السل أو غيرها من الإصابات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين: لعلاج مُشكلات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدبياغاتران: دواء لمنع تخثُّر الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكولشيسين: دواء لعلاج نوبات النُقرُص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البرافاستاتين، الروسوفاستاتين: أدوية لخفض مستويات الكوليسترول المرتفعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثوتريكسيت: دواء لعلاج التهاب المفاصل الحاد والسرطان والصدفية وأمراض الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلفاسالازين: دواء لعلاج التهاب الأمعاء والتهاب المفاصل الروماتيزمي الحاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإيفافرينيز، الإيترافيرين: أدوية لعلاج فيروس العوز المناعي البشري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المودافينيل: دواء لعلاج الخدار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البوسنتان: دواء لعلاج ارتفاع ضغط الدم الرئوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النافسيلين: دواء لعلاج الالتهابات البكتيريَّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفانتانيل: وفنتانيل: أدوية لعلاج الألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكينيدين: دواء لعلاج عدم انتظام ضرابات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين، السيروليموس، التاكروليموس: أدوية لتثبيط الجهاز المناعي.</p><p dir="RTL"><strong>الألونبريغ مع الطعام والشراب:</strong></p><p dir="RTL">تجنَّب تناوُل أي مُنتَج من مُنتجات الجريب فروت أثناء العلاج لأنها قد تغيِّر من كميَّة البريجاتينيب في دمك.</p><p dir="RTL"><strong>الحمل:</strong></p><p dir="RTL">&nbsp;لا يُنصًح بتناول دواء الألونبريغ أثناء الحمل ما لم يتم تغليب الفائدة من تعاطيه على الخطر على الجنين. إذا كنت حاملًا، أو تعتقدين بأنك من المحتمل أن تكونين حاملًا أو تخططين لإنجاب طفل؛ تحدثي إلى طبيبك لمناقشة مخاطر تناول دواء الألونبريغ أثناء الحمل.</p><p dir="RTL">ينبغي على النساء في سن الإنجاب ممن يُعالجن بدواء الألونبريغ تجنُّب حدوث الحمل. يتحتَّم استعمال وسائل منع الحمل الفعَّالة وغير الهرمونيَّة خلال العلاج ولمدة 4 شهور بعد توقُّف العلاج بدواء الألونبريغ. اسألي طبيبك عن طُرُق تحديد النسل التي قد تكون ملائمة لكِ.</p><p dir="RTL"><strong>الرضاعة الطبيعيَّة:</strong></p><p dir="RTL">لا ترضعي طفلك رضاعة طبيعيَّة خلال فترة العلاج بدواء الألونبريغ؛ فمن غير المعروف ما إذا كانت مادة البريجاتينيب تنتقل إلى حليب الأم ويمكن أن تسبب ضررًا مُحتملًا للطفل.</p><p dir="RTL"><strong>الخصوبة:</strong></p><p dir="RTL">يُنصَح الرجال ممن يُعالجون بدواء الألونبريغ بعدم محاولة إنجاب طفل أثناء العلاج واستخدام وسائل منع الحمل الفعَّالة خلال العلاج ولمدة 3 شهور بعد توقُّف العلاج.</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">قد يسبب دواء الألونبريغ الاضطرابات البصريَّة أو الدوخة أو التعب؛ فلا تقود أو تستخدم الآلات أثناء العلاج إذا ظهرت تلك الأعراض.</p><p dir="RTL"><strong>احتواء الألونبريغ على اللاكتوز:</strong></p><p dir="RTL">إذا أخبرك طبيبك بأنك لديك حساسية تجاه بعض السكريات؛ اتصل بطبيبك قبل تعاطي هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا وأبدًا كما أخبرك الطبيب أو الصيدلي، ناقش الأمر مع الطبيب أو الصيدلي إذا كنت مرتابًا في شيء.</p><p dir="RTL"><strong>الجُرعَة الموصى بها هي:</strong></p><p dir="RTL">قرص واحد يحتوي على 90 ملغم مرة واحدة يوميًا خلال أول 7 أيام من العلاج، وبعد ذلك قرص واحد يحتوي على 180 ملغم مرة واحدة يوميًا. لا تغيِّر الجُرعَة دون التحدُّث إلى طبيبك، وقد يكون طبيبك بحاجة إلى ضبط جُرعتَك وفقًا لاحتياجاتك، وقد يتطلَّب هذا الأمر استخدام قرص يحتوي على 30 ملغم لتحقيق الجُرعَة الجديدة الموصى بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول دواء ألونبريغ مرة واحدة يوميًّا في الوقت ذاته كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الأقراص بالكامل مع كوب من الماء. لا تسحق الأقراص أو تذيبها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول الأقراص مع الطعام أو دونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تقيَّأت بعد تناول دواء ألونبريغ؛ لا تتناول أي أقراص أخرى حتى موعد جُرعتك القادمة المُجَدوَلَة.</p><p dir="RTL"><strong>إذا أخذت جرعة من دواء ألونبريغ أكثر من الجُرعَة الواجب تناولها</strong></p><p dir="RTL">&nbsp;أخبِر طبيبك أو الصيدلي على الفور إذا كنت قد تناولت أقراصًا أكثر من الموصى بتناوُلها.</p><p dir="RTL"><strong>إذا نسيت تناول دواء ألونبريغ</strong></p><p dir="RTL">لا تتناول جُرعَة مُضَاعفَة لتعويض الجُرعَة المنسيَّة، وتناول جُرعتَك التالية في وقتك المُعتَاد.</p><p dir="RTL"><strong>إذا</strong> <strong>توقَّفت عن تناول دواء ألونبريغ</strong></p><p dir="RTL">لا تتوقَّف عن تعاطي دواء ألونبريغ قبل التحدُّث إلى طبيبك.</p><p dir="RTL">وإذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء؛ اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن لهذا الدواء أن يتسبب في إحداث آثار جانبيَّة مثله مثل جميع الأدوية بيد أنها لا تحدث جميع المرضى.</p><p dir="RTL">أخبر طبيبك أو الصيدلي على الفور إذا كان لديك أي من الآثار الجانبية الخطيرة التالية:</p><p dir="RTL">آثار جانبيَّة شائعة جدًا &ndash; (قد تؤثر على أكثر 1 من كل 10 أشخاص) كالآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم مرتفع.</p><p dir="RTL">أخبِر طبيبك إذا كُنت تُعاني من الصداع، أو الدوَّار، أو الرؤية الضبابيَّة، أو ألم في الصدر، أو ضيق في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الرؤية</p><p dir="RTL">أخبِر طبيبك إذا كُنت تعاني من أي اضطرابات بصريَّة مثل رؤية ومضات ضوئية، أو رؤية ضبابيَّة، أو ضوء يضر بعينيك. قد يوقف طبيبك العلاج بألونبريغ، ويحيلك إلى طبيب عيون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يشير زيادة مستوى الكيراتين فوسفوكينيز في الدم في الاختبارات إلى تلف العضلات مثل عضلات القلب. أخبر طبيبك إذا كُنت تُعاني من أي ألم غير مُبرر أو ليونة أو ضعف في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشير زيادة مستويات الأميليز أو الليبيز في الدم في الاختبارات إلى التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبِر طبيبَك إذا كُنت تُعاني من ألم في المنطقة العُليا من البطن بما في ذلك ألم البطن الذي يزداد سوءا مع الأكل وربما ينتشر إلى الظهر أو فقدان الوزن أو الغثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشير زيادة مستويات إنزيمات الكبد في الدم في الاختبارات (أسبارتات أمينوترانسفيريز، وألانين أمينوترانسفيريز) إلى تلف خلايا الكبد. أخبِر طبيبك إذا كُنت تُعاني من تلف في الجانب الأيمن من منطقة المعدة لديك، أو اصفرار بشرتك، أو ابيضاض عينيك، أو تحول لون البول لديك إلى لون قاتم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى السكر في الدم.</p><p dir="RTL">أخبِر طبيبَك إذا كُنت تشعر بالعطش الشديد، أو بحاجة إلى التبوُّل أكثر من المُعتاد، أو الشعور بالجوع الشديد، أو تشعر بعلة في معدتك أو ضعيف أو مُتعَب أو مشوَّش.</p><p dir="RTL">آثار جانبيَّة شائعة جدًا &ndash; (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص) كالآتي:</p><p dir="RTL">التهاب الرئتين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبِر طبيبَك إذا كُنت تُعاني من أي مُشكلات جديدة أو مُتفاقمة في الرئتين أو التنفس بما في ذلك آلام الصدر والسعال والحُمى وخصوصًا خلال الأسبوع الأول من العلاج بدواء ألونبريغ لأنها قد تكون إشارة إلى وجود مُشكلات خطيرة في الرئتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب</p><p dir="RTL">أخبِر طبيبَك إذا كان لديك ألم في الصدر أو الإحساس بعدم الارتياح أو تغيُّر في ضربات القلب أو دوخة أو دوَّار أو إغماء.</p><p dir="RTL">انظر أيضًا القسم 2 &quot;التحذيرات والاحتياطات&quot;</p><p dir="RTL">آثار جانبيَّة شائعة جدًا &ndash; (قد تؤثر على أكثر من 10 أشخاص) كالآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة (الالتهاب الرئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأعراض الشبيهة بنزلات البرد (عدوى الجهاز التنفسي العلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء التي تسمى العدلات والخلايا اللمفاوية في اختبارات الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة وقت تخثُّر الدم كما هو موضح باختبار زمن الثرومبوبلاستين الجزئي المنشط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية في اختبارات الدم مما قد يزيد من خطر النزيف والكدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الأنسولين في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الدم من الفوسفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الشهيَّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الدم من البوتاسيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض مستوى الدم من المغنيسيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الدم من الصوديوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الكالسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم (الأرق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مثل الإحساس بالخدر أو التنميل أو الإحساس بالوخز أو آلام في اليدين أو القدمين (الاعتلال العصبي المحيطي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السُعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم والشفتين (التهاب الفم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم الفوسفايز القلوي في الدم الأمر الذي يشير إلى وجود خلل في الأعضاء أو حدوث إصابة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل أو العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام عضلات الصدر الهيكليَّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكرياتينين في الدم الأمر الذي يشير إلى اضطراب وظائف الكليتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإعياء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الأنسجة الناجم عن السوائل الزائدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُمى.</p><p dir="RTL">آثار جانبيَّة شائعة &ndash; (قد تؤثِّر على ما يصل إلى 1 في كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الذاكرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير فيما يخص حاسة التذوُّق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة نبضات القلب (عدم انتظام ضربات القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نشاط كهربي غير طبيعي في القلب (فترة كهربية مطوَّلة للمسافة qt في التخطيط القلبي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْر الهضم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة لاكتيت الهيدروجينيز في الدم الأمر الذي يشير إلى تلف الأنسجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى البلوروبين في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلد الجاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية لضوء الشمس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين والقدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلُّب العضلات والمفاصِل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر وعدم الشعور بالراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p dir="RTL">آثار جانبيَّة غير شائعة &ndash; (قد تؤثر على ما يصل إلى 1 في كل 100 شخص) كالآتي:</p><p dir="RTL">آلام البنكرياس الأمر الذي قد يسبب ألامًا شديدة في المعدة مع أو دون وجود غثيان وقيء (التهاب البنكرياس).</p><p dir="RTL">الإبلاغ عن الآثار الجانبيَّة</p><p dir="RTL">إذا أصابتك أي آثار جانبيَّة؛ تحدَّث إلى طبيبك أو الصيدلي، ويشمل ذلك أي آثار جانبيَّة مُحتملَة غير مُدرَجَة في هذه النشرة. يمكنك توفير المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الآثار الجانبيَّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تخزِّن الدواء عند درجة حرارة أعلى من 30 درجة مئويَّة.</p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوَّن على اللاصقة أو الكرتونة بعد انتهاءه، ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من هذا الشهر.</p><p dir="RTL">لا تتخلَّص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزليَّة. اسأل الصيدلي عن كيفيَّة التخلُّص من الأدوية التي لم تعد تستخدمها، ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات عبوَّة ألونبريغ</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي البريجاتينيب</p><p dir="RTL">يحتوي كل قرص 30 ملغم مُغلَّف بطبقة رقيقة على 30 ملغم من البريجاتينيب.</p><p dir="RTL">يحتوي كل قرص 90 ملغم مُغلَّف بطبقة رقيقة على 90 ملغم من البريجاتينيب.</p><p dir="RTL">يحتوي كل قرص 180 ملغم مُغلَّف بطبقة رقيقة على 180 ملغم من البريجاتينيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتشمل المكونات الأخرى على اللاكتوز أُحادي الإماهة، السليولوز دقيق البللورات، غليكولات نشا الصوديوم (نوع أ)، السيليكا الغروانية الكارهة للماء، سيترات الماغنسيوم، التلك، الماكروجول، الكحول عديد الفينيل، وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وثاني أكسيد التيتانيوم.</p><p dir="RTL"><strong>كيف يبدو دواء </strong><strong>ألونبريغ وما هي محتويات العبوَّة</strong></p><p dir="RTL">أقراص ألونبريغ المُغلَّفة لونها من الأبيض إلى الكريمي وبيضاوية الشكل (90 و180 ملغم)، أو دائريَّة الشكل (30 ملغم)، ومحدبة على الجانبين العلوي والسفلي.</p><p dir="RTL">ألونبريغ 30 ملغم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص 30 ملغم مُغلَّف على 30 ملغم من البريجاتينيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يبلُغ قُطر الأقراص المُغلَّفة 7 ملم تقريبًا مع وجود (U3) على جانب واحد، وملساء من الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ألونبريغ 90 ملغم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص 90 ملغم مُغلَّف على 90 ملغم من البريجاتينيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يبلُغ طول الأقراص المُغلَّفة 7 ملم تقريبًا مع وجود (U7) على جانب واحد، وملساء من الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ألونبريغ 180 ملغم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص 180 ملغم مُغلَّف على 180 ملغم من البريجاتينيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يبلُغ طول الأقراص المُغلَّفة 19 ملم تقريبًا مع وجود (U13) على جانب واحد، وملساء من الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوافر الأقراص في شرائط من البلاستيك المُغطى برقائق معدنية (فقاعية) معبأة في كرتون مع وجود:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألونبريغ 30 ملغم: 28 قرص مُغلَّف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألونبريغ 90 ملغم: 7 أو 28 قرص مُغلَّف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألونبريغ 180 ملغم: 28 قرص مُغلَّف.</p><p dir="RTL">قد لا يُجرى تسويق جميع العبوَّات بجميع الأحجام.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Takeda Pharma A/S</p><p dir="RTL">Dybendal Alle 10</p><p dir="RTL">2630 Taastrup</p><p dir="RTL">Denmark</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>المُصنِّع:</strong></p><p dir="RTL">Penn Pharmaceutical Services Ltd.</p><p dir="RTL">&nbsp;Units 23-24 Tafarnaubach Industrial Estate</p><p dir="RTL">Tafarnaubach, Tredegar</p><p dir="RTL">NP22 3AA, United Kingdom (GBR)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موقع التعبئة والتغليف و</strong><strong>الافراج النهائي</strong><strong>:</strong></p><p dir="RTL">Takeda Austria GmbH</p><p dir="RTL">St. Peter‑Strasse 25</p><p dir="RTL">4020 Linz</p><p dir="RTL">Austria</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في يناير 2020.  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
	Alunbrig 180 mg film coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
	Alunbrig 180 mg film coated tablets
	Each film coated tablet contains 180 mg of brigatinib.
	
	Excipient with known effect
	Each film coated tablet contains 336 mg of lactose monohydrate.
	
	For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Film coated tablet (tablet).
	
		
	Alunbrig 180 mg film coated tablets
	Oval, white to off white film coated tablet of approximately 19 mm in length with debossed “U13” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously treated with crizotinib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Alunbrig should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.</p><p>&nbsp;</p><p>ALK‑positive NSCLC status should be known prior to initiation of Alunbrig therapy. A validated ALK assay is necessary for the selection of ALK‑positive NSCLC patients (see section&nbsp;5.1). Assessment for ALK‑positive NSCLC should be performed by laboratories with demonstrated proficiency in the specific technology being utilised.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended starting dose of Alunbrig is 90&nbsp;mg once daily for the first 7&nbsp;days, then 180&nbsp;mg once daily.</p><p>&nbsp;</p><p>If Alunbrig is interrupted for 14&nbsp;days or longer for reasons other than adverse reactions, treatment should be resumed at 90&nbsp;mg once daily for 7&nbsp;days before increasing to the previously tolerated dose.</p><p>&nbsp;</p><p>If a dose is missed or vomiting occurs after taking a dose, an additional dose should not be administered and the next dose should be taken at the scheduled time.</p><p>&nbsp;</p><p>Treatment should continue as long as clinical benefit is observed.</p><p>&nbsp;</p><p><em><u>Dose adjustments</u></em></p><p>&nbsp;</p><p>Dosing interruption and/or dose reduction may be required based on individual safety and tolerability.</p><p>&nbsp;</p><p>Alunbrig dose modification levels are summarised in Table&nbsp;1.</p><p>&nbsp;</p><p><strong>Table&nbsp;1: Recommended Alunbrig dose reduction levels</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Dose</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Dose reduction levels</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>First</strong></p></td><td style="vertical-align:top"><p><strong>Second</strong></p></td><td style="vertical-align:top"><p><strong>Third</strong></p></td></tr><tr><td style="vertical-align:top"><p>90&nbsp;mg once daily</p><p>(first 7&nbsp;days)</p></td><td style="vertical-align:top"><p>reduce to 60&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>permanently discontinue</p></td><td style="vertical-align:top"><p>not applicable</p></td></tr><tr><td style="vertical-align:top"><p>180&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>reduce to 120&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>reduce to 90&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>reduce to 60&nbsp;mg once daily</p></td></tr></tbody></table><p>&nbsp;</p><p>Alunbrig should be permanently discontinued if patient is unable to tolerate the 60&nbsp;mg once daily dose.</p><p>&nbsp;</p><p>Recommendations for dose modifications of Alunbrig for the management of adverse reactions are summarised in Table&nbsp;2.</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Recommended Alunbrig dose modifications for adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:101%"><thead><tr><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Severity</strong>*</p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Interstitial lung disease (ILD)/pneumonitis</p></td><td style="vertical-align:top"><p>Grade&nbsp;1</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If event occurs during the first 7&nbsp;days of treatment, Alunbrig should be withheld until recovery to baseline, then resumed at same dose level and not escalated to 180&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ILD/pneumonitis occurs after the first 7&nbsp;days of treatment, Alunbrig should be withheld until recovery to baseline, then resumed at same dose level.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ILD/pneumonitis recurs, Alunbrig should be permanently discontinued.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ILD/pneumonitis occurs during the first 7&nbsp;days of treatment, Alunbrig should be withheld until recovery to baseline, then resumed at next lower dose level as described in Table&nbsp;1 and not escalated to 180&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ILD/pneumonitis occurs after the first 7&nbsp;days of treatment, Alunbrig should be withheld until recovery to baseline. Alunbrig should be resumed at next lower dose level as described in Table&nbsp;1.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ILD/pneumonitis recurs, Alunbrig should be permanently discontinued.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3&nbsp;or&nbsp;4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be permanently discontinued.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Grade&nbsp;3 hypertension<br />(SBP&nbsp;&ge;&nbsp;160&nbsp;mmHg or DBP&nbsp;&ge;&nbsp;100&nbsp;mmHg, medical intervention indicated, more than one anti‑hypertensive medicinal product, or more intensive therapy than previously used indicated)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until hypertension has recovered to Grade&nbsp;&le;&nbsp;1 (SBP&nbsp;&lt;&nbsp;140&nbsp;mmHg and DBP&nbsp;&lt;&nbsp;90&nbsp;mmHg), then resumed at same dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If Grade&nbsp;3 hypertension recurs, Alunbrig should be withheld until hypertension has recovered to Grade&nbsp;&le;&nbsp;1 then resumed at the next lower dose level per Table&nbsp;1 or permanently discontinued</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 hypertension<br />(life threatening consequences, urgent intervention indicated)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until hypertension has recovered to Grade&nbsp;&le;&nbsp;1 (SBP&nbsp;&lt;&nbsp;140&nbsp;mmHg and DBP&nbsp;&lt;&nbsp;90&nbsp;mmHg), then resumed at the next lower dose level per Table&nbsp;1 or permanently discontinued.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If Grade&nbsp;4 hypertension recurs, Alunbrig should be permanently discontinued.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Bradycardia (HR less than 60&nbsp;bpm)</p></td><td style="vertical-align:top"><p>Symptomatic bradycardia</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to asymptomatic bradycardia or to a resting heart rate of 60&nbsp;bpm or above.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If a concomitant medicinal product known to cause bradycardia is identified and discontinued, or its dose is adjusted, Alunbrig should be resumed at same dose upon recovery to asymptomatic bradycardia or to a resting heart rate of 60&nbsp;bpm or above.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no concomitant medicinal product known to cause bradycardia is identified, or if contributing concomitant medications are not discontinued or dose modified, Alunbrig should be resumed at the next lower dose level per Table&nbsp;1 upon recovery to asymptomatic bradycardia or to a resting heart rate of 60&nbsp;bpm or above.</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia with life‑threatening consequences, urgent intervention indicated</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, Alunbrig should be resumed at the next lower dose level per Table&nbsp;1 upon recovery to asymptomatic bradycardia or to a resting heart rate of 60&nbsp;bpm or above, with frequent monitoring as clinically indicated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be permanently discontinued if no contributing concomitant medicinal product is identified.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be permanently discontinued in case of recurrence.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Elevation of CPK</p></td><td style="vertical-align:top"><p>Grade&nbsp;3 elevation of CPK (&gt;&nbsp;5.0&nbsp;&times;&nbsp;ULN)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to Grade&nbsp;&le;&nbsp;1 (&le;&nbsp;2.5&nbsp;&times;&nbsp;ULN) or to baseline, then resumed at the same dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If Grade&nbsp;3 elevation of CPK recurs, Alunbrig should be withheld until recovery to Grade&nbsp;&le;&nbsp;1 (&le;&nbsp;2.5&nbsp;&times;&nbsp;ULN) or to baseline, then resumed at the next lower dose level per Table&nbsp;1.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 elevation of CPK (&gt;&nbsp;10.0&nbsp;&times;&nbsp;ULN)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to Grade&nbsp;&le;&nbsp;1 (&le;&nbsp;2.5&nbsp;&times;&nbsp;ULN) or to baseline, then resumed at the next lower dose level per Table&nbsp;1.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Elevation of lipase or amylase</p></td><td style="vertical-align:top"><p>Grade&nbsp;3 elevation of lipase or amylase (&gt;&nbsp;2.0&nbsp;&times;&nbsp;ULN)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to Grade&nbsp;&le;&nbsp;1 (&le;&nbsp;1.5&nbsp;&times;&nbsp;ULN) or to baseline, then resumed at same dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If Grade&nbsp;3 elevation of lipase or amylase recurs, Alunbrig should be withheld until recovery to Grade&nbsp;&le;&nbsp;1 (&le;&nbsp;1.5&nbsp;&times;&nbsp;ULN) or to baseline, then resumed at the next lower dose level per Table&nbsp;1.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 elevation of lipase or amylase (&gt;&nbsp;5.0&nbsp;x&nbsp;ULN)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to Grade&nbsp;&le;&nbsp;1 (&le;&nbsp;1.5&nbsp;&times;&nbsp;ULN), then resumed at the next lower dose level per Table&nbsp;1.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatotoxicity</p></td><td style="vertical-align:top"><p>Grade&nbsp;<strong>&ge;</strong>&nbsp;3 elevation (&gt;&nbsp;5.0&nbsp;&times;&nbsp;ULN) of either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) with bilirubin &pound;&nbsp;2&nbsp;&times;&nbsp;ULN</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to baseline or less than or equal to 3&nbsp;&times;&nbsp;ULN, then resumed at next lower dose per Table&nbsp;1.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;<strong>&ge;</strong>&nbsp;2 elevation (&gt;&nbsp;3&nbsp;&times;&nbsp;ULN)&nbsp;of ALT or AST with concurrent total bilirubin elevation&nbsp;<strong>&gt;&nbsp;</strong>2&nbsp;&times;&nbsp;ULN in the absence of cholestasis or haemolysis</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be permanently discontinued.</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>For Grade&nbsp;3 (greater than 250&nbsp;mg/dL or 13.9&nbsp;mmol/L) or greater</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If adequate hyperglycaemic control cannot be achieved with optimal medical management, Alunbrig should be withheld until adequate hyperglycaemic control is achieved. Upon recovery, Alunbrig may either be resumed at the next lower dose per Table&nbsp;1 or permanently discontinued.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Visual Disturbance</p></td><td style="vertical-align:top"><p>Grade&nbsp;2 or&nbsp;3</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to Grade&nbsp;1 or baseline, then resumed at the next lower dose level per Table&nbsp;1.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be permanently discontinued.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Other adverse reactions</p></td><td style="vertical-align:top"><p>Grade&nbsp;3</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to baseline, then resumed at the same dose level.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the Grade&nbsp;3 event recurs, Alunbrig should be withheld until recovery to baseline, then resumed at the next lower dose level as per Table&nbsp;1 or permanently discontinued.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alunbrig should be withheld until recovery to baseline, then resumed at the next lower dose level as per Table&nbsp;1.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the Grade&nbsp;4 event recurs, Alunbrig should be withheld until recovery to baseline, then resumed at the next lower dose level as per Table&nbsp;1 or permanently discontinued.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>bpm&nbsp;=&nbsp;beats per minute; CPK&nbsp;=&nbsp;Creatine Phosphokinase; DBP&nbsp;=&nbsp;diastolic blood pressure; HR&nbsp;=&nbsp;heart rate; SBP&nbsp;=&nbsp;systolic blood pressure; ULN&nbsp;=&nbsp;upper limit of normal</p></td></tr></tbody></table><p>*Graded per National Cancer Institute Common Terminology Criteria for Adverse Events. Version&nbsp;4.0 (NCI CTCAE v4).</p><p><em>&nbsp;</em></p><p><em><u>Special populations</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Elderly patients</em></p><p>The limited data on the safety and efficacy of Alunbrig in patients aged 65&nbsp;years and older suggest that a dose adjustment is not required in elderly patients (see section&nbsp;4.8). There are no available data on patients over 85&nbsp;years of age.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of Alunbrig is required for patients with mild hepatic impairment (Child‑Pugh class A) or moderate hepatic impairment (Child‑Pugh class B). A reduced starting dose of 60&nbsp;mg once daily for the first 7&nbsp;days, then 120&nbsp;mg once daily is recommended for patients with severe hepatic impairment (Child‑Pugh class C) (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of Alunbrig is required for patients with mild or moderate renal impairment (estimated glomerular filtration rate (eGFR)&nbsp;&ge;&nbsp;30&nbsp;mL/min). A reduced starting dose of 60&nbsp;mg once daily for the first 7&nbsp;days, then 90&nbsp;mg once daily is recommended for patients with severe renal impairment (eGFR&nbsp;&lt;&nbsp;30&nbsp;mL/min) (see section&nbsp;5.2). Patients with severe renal impairment should be closely monitored for new or worsening respiratory symptoms that may indicate ILD/pneumonitis (e.g., dyspnoea, cough, etc.) particularly in the first week (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Alunbrig in patients less than 18&nbsp;years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Alunbrig is for oral use. The tablets should be swallowed whole and with water. Alunbrig may be taken with or without food.</p><p>&nbsp;</p><p>Grapefruit or grapefruit juice may increase plasma concentrations of brigatinib and should be avoided (see section&nbsp;4.5).<s> </s></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pulmonary adverse reactions</u></p><p>Severe, life‑threatening, and fatal pulmonary adverse reactions, including those with features consistent with ILD/pneumonitis, can occur in patients treated with Alunbrig (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Most pulmonary adverse reactions were observed within the first 7&nbsp;days of treatment. Grade&nbsp;1‑2 pulmonary adverse reactions resolved with interruption of treatment or dose modification. Increased age and shorter interval (less than 7&nbsp;days) between the last dose of crizotinib and the first dose of Alunbrig were independently associated with an increased rate of these pulmonary adverse reactions. These factors should be considered when initiating treatment with Alunbrig. Patients with a history of ILD or drug‑induced pneumonitis were excluded from the pivotal trial.</p><p>&nbsp;</p><p>Some patients experienced pneumonitis later in treatment with Alunbrig.</p><p>&nbsp;</p><p>Patients should be monitored for new or worsening respiratory symptoms (e.g., dyspnoea, cough,<strong> </strong>etc.), particularly in the first week of treatment. Evidence of pneumonitis in any patient with worsening respiratory symptoms should be promptly investigated. If pneumonitis is suspected, the dose of Alunbrig should be withheld, and the patient evaluated for other causes of symptoms (e.g., pulmonary embolism, tumour progression, and infectious pneumonia). The dose should be modified accordingly (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Hypertension</u></p><p>Hypertension has occurred in patients treated with Alunbrig (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Blood pressure should be monitored regularly during treatment with Alunbrig. Hypertension should be treated according to standard guidelines to control blood pressure. Heart rate should be monitored more frequently in patients if concomitant use of a medicinal product known to cause bradycardia cannot be avoided. For severe hypertension (&ge;&nbsp;Grade&nbsp;3), Alunbrig should be withheld until hypertension has recovered to Grade&nbsp;1 or to baseline. The dose should be modified accordingly (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Bradycardia</u></p><p>Bradycardia has occurred in patients treated with Alunbrig (see section&nbsp;4.8). Caution should be exercised when administering Alunbrig in combination with other agents known to cause bradycardia. Heart rate and blood pressure should be monitored regularly.</p><p>&nbsp;</p><p>If symptomatic bradycardia occurs, treatment with Alunbrig should be withheld and concomitant medicinal products known to cause bradycardia should be evaluated. Upon recovery, the dose should be modified accordingly (see section&nbsp;4.2). In case of life‑threatening bradycardia, if no contributing concomitant medication is identified or in case of recurrence, treatment with Alunbrig should be discontinued (see section&nbsp;4.2)<em>.</em></p><p>&nbsp;</p><p><u>Visual disturbance</u></p><p>Visual disturbance adverse reactions have occurred in patients treated with Alunbrig (see section&nbsp;4.8). Patients should be advised to report any visual symptoms. For new or worsening severe visual symptoms, an ophthalmologic evaluation and dose reduction should be considered<em> </em>(see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Creatine phosphokinase (CPK) elevation</u></p><p>Elevations of CPK have occurred in patients treated with Alunbrig (see section&nbsp;4.8). Patients should be advised to report any unexplained muscle pain, tenderness, or weakness. CPK levels should be monitored regularly during Alunbrig treatment. Based on the severity of the CPK elevation, treatment with Alunbrig should be withheld, and the dose modified accordingly (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Elevations of pancreatic enzymes</u></p><p>Elevations of amylase and lipase have occurred in patients treated with Alunbrig (see section&nbsp;4.8). Lipase and amylase should be monitored regularly during treatment with Alunbrig. Based on the severity of the laboratory abnormalities, treatment with Alunbrig should be withheld, and the dose modified accordingly (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Hepatotoxicity</u></p><p>Elevations of hepatic enzymes (aspartate aminotransferase, alanine aminotransferase) and bilirubin have occurred in patients treated with Alunbrig (see section&nbsp;4.8). Liver function, including AST, ALT and total bilirubin should be assessed prior to the initiation of Alunbrig and then every 2&nbsp;weeks during the first 3&nbsp;months of treatment. Thereafter, monitoring should be performed periodically. Based on the severity of the laboratory abnormalities, treatment should be withheld, and the dose modified accordingly (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Hyperglycaemia</u></p><p>Elevations of serum glucose have occurred in patients treated with Alunbrig. Fasting serum glucose should be assessed prior to initiation of Alunbrig and monitored periodically thereafter. Antihyperglycaemic treatment should be initiated or optimised as needed. If adequate hyperglycaemic control cannot be achieved with optimal medical management, Alunbrig should be withheld until adequate hyperglycaemic control is achieved; upon recovery reducing the dose as described in Table&nbsp;1 may be considered or Alunbrig may be permanently discontinued.</p><p>&nbsp;</p><p><u>Drug‑drug interactions</u></p><p>The concomitant use of Alunbrig with strong CYP3A inhibitors should be avoided. If concomitant use of strong CYP3A inhibitors cannot be avoided, the dose of Alunbrig should be reduced from 180&nbsp;mg to 90&nbsp;mg, or from 90&nbsp;mg to 60&nbsp;mg. After discontinuation of a strong CYP3A inhibitor, Alunbrig should be resumed at the dose that was tolerated prior to the initiation of the strong CYP3A inhibitor.</p><p>&nbsp;</p><p>The concomitant use of Alunbrig with strong and moderate CYP3A inducers should be avoided (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Women of childbearing potential should be advised to use effective non‑hormonal contraception during treatment with Alunbrig and for at least 4 months following the final dose. Men with female partners of childbearing potential should be advised to use effective contraception during treatment and for at least 3 months after the last dose of Alunbrig (see section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Lactose</u></p><p>Alunbrig contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Agents that may increase brigatinib plasma concentrations</u></p><p><u>&nbsp;</u></p><p><em><u>CYP3A inhibitors</u></em></p><p><em>In vitro</em> studies demonstrated that brigatinib is a substrate of CYP3A4/5. In healthy subjects, coadministration of multiple 200&nbsp;mg twice daily doses of itraconazole, a strong CYP3A inhibitor, with a single 90&nbsp;mg brigatinib dose increased brigatinib C<sub>max</sub> by 21%, AUC<sub>0‑INF </sub>by 101% (2‑fold), and AUC<sub>0‑120 </sub>by 82% (&lt;&nbsp;2‑fold), relative to a 90&nbsp;mg brigatinib dose administered alone. The concomitant use of strong CYP3A inhibitors with Alunbrig, including but not limited to certain antivirals (e.g., indinavir, nelfinavir, ritonavir, saquinavir), macrolide antibiotics (e.g., clarithromycin, telithromycin, troleandomycin), antifungals (e.g., ketoconazole, voriconazole), mibefradil, and nefazodone should be avoided. If concomitant use of strong CYP3A inhibitors cannot be avoided, the dose of Alunbrig should be reduced by approximately 50% (i.e. from 180&nbsp;mg to 90&nbsp;mg, or from 90&nbsp;mg to 60&nbsp;mg). After discontinuation of a strong CYP3A inhibitor, Alunbrig should be resumed at the dose that was tolerated prior to the initiation of the strong CYP3A inhibitor.</p><p>&nbsp;</p><p>Moderate CYP3A inhibitors (e.g., diltiazem and verapamil) may increase the AUC of brigatinib by approximately 40% based on simulations from a physiologically‑based pharmacokinetic model. No dose adjustment is required for Alunbrig in combination with moderate CYP3A inhibitors. Patients should be closely monitored when Alunbrig is coadministered with moderate CYP3A inhibitors.</p><p>&nbsp;</p><p>Grapefruit or grapefruit juice may also increase plasma concentrations of brigatinib and should be avoided (see section&nbsp;4.2).</p><p><u>&nbsp;</u></p><p><em><u>CYP2C8 inhibitors</u></em></p><p><em>In vitro</em> studies demonstrated that brigatinib is a substrate of CYP2C8. In healthy subjects, coadministration of multiple 600&nbsp;mg twice daily doses of gemfibrozil, a strong CYP2C8 inhibitor, with a single 90&nbsp;mg brigatinib dose reduced brigatinib C<sub>max</sub> by 41%, AUC<sub>0‑INF </sub>by 12%, and AUC<sub>0‑120</sub> by 15%, relative to a 90&nbsp;mg brigatinib dose administered alone. The effect of gemfibrozil on the pharmacokinetics of brigatinib is not clinically meaningful and the underlying mechanism for the decreased exposure of brigatinib is unknown. No dose adjustment is required during coadministration with strong CYP2C8 inhibitors.</p><p>&nbsp;</p><p><em><u>P‑gp and BCRP inhibitors</u></em></p><p>Brigatinib is a substrate of P‑glycoprotein (P‑gp) and breast cancer resistance protein (BCRP) <em>in vitro</em>. Given that brigatinib exhibits high solubility and high permeability, inhibition of P‑gp and BCRP is not expected to result in a clinically meaningful change in the systemic exposure of brigatinib. No dose adjustment is required for Alunbrig during coadministration with P‑gp and BCRP inhibitors.</p><p>&nbsp;</p><p><u>Agents that may decrease brigatinib plasma concentrations</u></p><p><u>&nbsp;</u></p><p><em><u>CYP3A inducers</u></em></p><p>In healthy subjects, coadministration of multiple 600&nbsp;mg daily doses of rifampicin, a strong CYP3A inducer, with a single 180&nbsp;mg brigatinib dose decreased brigatinib C<sub>max</sub> by 60%, AUC<sub>0‑INF </sub>by 80% (5‑fold), and AUC<sub>0‑120</sub> by 80% (5‑fold), relative to a 180&nbsp;mg brigatinib dose administered alone. The concomitant use of strong CYP3A inducers with Alunbrig, including but not limited to rifampicin, carbamazepine, phenytoin, rifabutin, phenobarbital, and St. John&rsquo;s wort should be avoided.</p><p>&nbsp;</p><p>Moderate CYP3A inducers may decrease the AUC of brigatinib by approximately 50% based on simulations from a physiologically‑based pharmacokinetic model. The concomitant use of moderate CYP3A inducers with Alunbrig, including but not limited to efavirenz, modafinil, bosentan, etravirine, and nafcillin should be avoided.</p><p>&nbsp;</p><p><u>Agents that may have their plasma concentrations altered by brigatinib</u></p><p><u>&nbsp;</u></p><p><em><u>CYP3A substrates</u></em></p><p><em>In vitro</em> studies in hepatocytes have shown that brigatinib is an inducer of CYP3A4. Clinical drug‑drug interaction studies with CYP3A sensitive substrates have not been conducted. Brigatinib may reduce plasma levels of coadministered medicinal products that are predominantly metabolised by CYP3A. Therefore, coadministration of Alunbrig with CYP3A substrates with a narrow therapeutic index (e.g., alfentanil, fentanyl, quinidine, cyclosporine, sirolimus, tacrolimus) should be avoided as their effectiveness may be reduced.</p><p>&nbsp;</p><p>Alunbrig may also induce other enzymes and transporters (e.g., CYP2C, P‑gp) via the same mechanisms responsible for induction of CYP3A (e.g., pregnane X receptor activation).</p><p>&nbsp;</p><p><em><u>Transporter substrates</u></em></p><p>Coadministration of brigatinib with substrates of P‑gp, (e.g., digoxin, dabigatran, colchicine, pravastatin), BCRP (e.g., methotrexate, rosuvastatin, sulfasalazine), organic cation transporter 1 (OCT1), multidrug and toxin extrusion protein 1 (MATE1), and 2K (MATE2K) may increase their plasma concentrations. Patients should be closely monitored when Alunbrig is coadministered with substrates of these transporters with a narrow therapeutic index (e.g., digoxin, dabigatran, methotrexate).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>&nbsp;</p><p>Women of childbearing age being treated with Alunbrig should be advised not to become pregnant and men being treated with Alunbrig should be advised not to father a child during treatment. Women of reproductive potential should be advised to use effective non‑hormonal contraception during treatment with Alunbrig and for at least 4&nbsp;months following the final dose. Men with female partners of reproductive potential should be advised to use effective contraception during treatment and for at least 3&nbsp;months after the last dose of Alunbrig.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Alunbrig may cause foetal harm when administered to a pregnant woman. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3). There are no clinical data on the use of Alunbrig in pregnant women. Alunbrig should not be used during pregnancy unless the clinical condition of the mother requires treatment. If Alunbrig is used during pregnancy, or if the patient becomes pregnant while taking this medicinal product, the patient should be apprised of the potential hazard to a foetus.</p><p><u>&nbsp;</u></p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether Alunbrig is excreted in human milk. Available data cannot exclude potential excretion in human milk. Breast‑feeding should be stopped during treatment with Alunbrig.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No human data on the effect of Alunbrig on fertility are available. Based on repeat‑dose toxicity studies in male animals, Alunbrig may cause reduced fertility in males (see section&nbsp;5.3). The clinical relevance of these findings to human fertility is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alunbrig has minor influence on the ability to drive and use machines. However, caution should be exercised when driving or operating machines as patients may experience visual disturbance, dizziness, or fatigue while taking Alunbrig.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The adverse reactions described in this section were identified from two clinical trials:</p><p><em>Study 201 (ALTA)</em>: A randomised, open‑label, multicentre trial in patients treated with Alunbrig (N&nbsp;=&nbsp;219) with ALK+&nbsp;NSCLC who previously progressed on crizotinib. Patients were randomised in a 1:1&nbsp;ratio to receive Alunbrig either 90&nbsp;mg once daily continuously (90&nbsp;mg regimen) or 180&nbsp;mg once daily with 7‑day lead‑in at 90&nbsp;mg once daily (180&nbsp;mg regimen).</p><p><em>Study 101</em>: An open‑label multicentre phase&nbsp;1/2 dose escalation/expansion trial in patients with advanced malignancies.</p><p>&nbsp;</p><p>The most common adverse reactions (&ge;&nbsp;25%) reported in patients treated with Alunbrig at the recommended dosing regimen were increased AST, hyperglycaemia, hyperinsulinaemia, anaemia, increased CPK, nausea, increased lipase, decreased lymphocyte count, increased ALT, diarrhoea, increased amylase, fatigue, cough, headache, increased alkaline phosphatase, hypophosphataemia, increased APTT, rash, vomiting, dyspnoea, hypertension, decreased white blood cell count, myalgia, and peripheral neuropathy.</p><p>&nbsp;</p><p>The most common serious adverse reactions (&ge;&nbsp;2%) reported in patients treated with Alunbrig at the recommended dosing regimen other than events related to neoplasm progression were pneumonitis, pneumonia, and dyspnoea.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions </u></p><p>&nbsp;</p><p>Adverse reactions reported in ALTA and Study 101 at the recommended dosing regimen are presented in Table&nbsp;3 and are listed by system organ class, preferred term and frequency. Frequency categories are very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to&nbsp;&lt;&nbsp;1/10) and uncommon (&ge;&nbsp;1/1,000 to&nbsp;&lt;&nbsp;1/100). Within each frequency grouping, undesirable effects are presented in order of frequency.</p><p>&nbsp;</p><p><strong>Table&nbsp;3: Adverse reactions reported in patients treated with Alunbrig in ALTA and Study 101 (per Common Terminology Criteria for Adverse Events (CTCAE) version&nbsp;4.0)</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Frequency</strong></p><p><strong>category</strong></p></td><td><p><strong>Adverse reactions<sup>&dagger; </sup></strong></p><p><strong>all grades</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p><p><strong>Grade&nbsp;3‑4</strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pneumonia<sup>a</sup></p><p>Upper respiratory tract infection</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pneumonia<sup>a</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia</p><p>Lymphocyte count decreased</p><p>APTT increased</p><p>White blood cell count decreased</p><p>Neutrophil count decreased</p><p>Decreased platelet count</p></td><td style="vertical-align:top"><p>Lymphocyte count decreased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>APTT increased</p><p>Anaemia</p><p>Neutrophil count decreased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hyperinsulinaemia<sup>b</sup></p><p>Hypophosphataemia</p><p>Decreased appetite</p><p>Hypokalaemia</p><p>Hypomagnesaemia</p><p>Hyponatraemia</p><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypophosphataemia</p><p>Hyperglycaemia</p><p>Hyponatraemia</p><p>Hypokalaemia</p><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache<sup>c</sup></p><p>Peripheral neuropathy<sup>d</sup></p><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Memory impairment</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Peripheral neuropathy<sup>d</sup></p><p>Headache<sup>c</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Visual disturbance<sup>e</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbance<sup>e</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tachycardia<sup>f</sup></p><p>Electrocardiogram QT prolonged</p><p>Bradycardia<sup>g</sup></p><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Cough</p><p>Dyspnoea<sup>h</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pneumonitis<sup>i</sup></p></td><td style="vertical-align:top"><p>Pneumonitis<sup>i</sup></p><p>Dyspnoea<sup>h</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Lipase increased</p><p>Nausea</p><p>Diarrhoea<sup>j</sup></p><p>Amylase increased</p><p>Vomiting</p><p>Constipation</p><p>Abdominal pain<sup>k</sup></p><p>Dry mouth</p><p>Stomatitis<sup>l</sup></p></td><td style="vertical-align:top"><p>Lipase increased</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspepsia</p><p>Flatulence</p></td><td style="vertical-align:top"><p>Amylase increased</p><p>Abdominal pain<sup>k</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Nausea</p><p>Dyspepsia</p><p>Pancreatitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>AST increased</p><p>ALT increased</p><p>Alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood lactate dehydrogenase increased</p><p>Hyperbilirubinaemia</p></td><td style="vertical-align:top"><p>ALT increased</p><p>AST increased</p><p>Alkaline phosphatase increased</p><p>Hyperbilirubinaemia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Rash<sup>m</sup></p><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dry skin</p><p>Photosensitivity reaction</p></td><td style="vertical-align:top"><p>Rash<sup>m</sup></p><p>Photosensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry skin</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Blood CPK increased</p><p>Myalgia<sup>n</sup></p><p>Arthralgia</p><p>Musculoskeletal chest pain</p></td><td style="vertical-align:top"><p>Blood CPK increased</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pain in extremity</p><p>Musculoskeletal stiffness</p></td><td style="vertical-align:top"><p>Pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia<sup>n</sup></p><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue<sup>o</sup></p><p>Oedema<sup>p</sup></p><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pain</p><p>Non‑cardiac&nbsp;chest&nbsp;pain</p><p>Chest discomfort</p></td><td style="vertical-align:top"><p>Fatigue<sup>o</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Non‑cardiac&nbsp;chest&nbsp;pain</p><p>Pyrexia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decreased</p></td></tr><tr><td colspan="4"><p><sup>a</sup><sup> </sup>Includes atypical pneumonia, pneumonia, pneumonia aspiration, pneumonia pseudomonal, lower respiratory tract infection, lower respiratory tract infection viral, lung infection</p><p><sup>b</sup> Grade not applicable</p><p><sup>c</sup><sup> </sup>Includes headache, sinus headache, head discomfort, migraine, tension headache</p><p><sup>d</sup> Includes paraesthesia, peripheral sensory neuropathy, dysaesthesia, hyperaesthesia, hypoaesthesia, neuralgia, neuropathy peripheral, neurotoxicity, peripheral motor neuropathy, polyneuropathy</p><p><sup>e</sup> Includes altered visual depth perception, asthenopia, cataract, colour blindness acquired, diplopia, glaucoma, intraocular pressure increased, macular oedema, photophobia, photopsia, retinal oedema, vision blurred, visual acuity reduced, visual field defect, visual impairment, vitreous detachment, vitreous floaters, amaurosis fugax</p><p><sup>f </sup>Includes sinus tachycardia, tachycardia</p><p><sup>g</sup> Includes bradycardia, sinus bradycardia</p><p><sup>h </sup>Includes dyspnoea, dyspnoea exertional</p><p><sup>i </sup>Includes interstitial lung disease, pneumonitis</p><p><sup>j </sup>Includes diarrhoea, diarrhoea infectious</p><p><sup>k</sup> Includes abdominal discomfort, abdominal distension, abdominal pain, abdominal pain lower, abdominal pain upper, epigastric discomfort</p><p><sup>l </sup>Includes aphthous stomatitis, stomatitis, aphthous ulcer, mouth ulceration, oral mucosal blistering</p><p><sup>m </sup>Includes dermatitis acneiform, erythema, exfoliative rash, rash, rash erythematous, rash macular, rash maculo‑papular, rash papular, rash pruritic, rash pustular, dermatitis, dermatitis allergic, generalised erythema, rash follicular, urticaria</p><p><sup>n </sup>Includes musculoskeletal pain, myalgia, muscle spasms, muscle tightness, muscle twitching, musculoskeletal discomfort</p><p><sup>o </sup>Includes asthenia, fatigue</p><p><sup>p </sup>Includes eyelid oedema, face oedema, localised oedema, oedema peripheral, periorbital oedema, swelling face, generalised oedema, peripheral swelling</p><p><sup>&dagger; </sup>The frequencies for ADR terms associated with chemistry and haematology laboratory changes were determined based on the frequency of abnormal laboratory shifts from baseline.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><u>Description of selected adverse reactions</u></p><p><strong>&nbsp;</strong></p><p><em><u>Pulmonary adverse reactions</u></em></p><p>In ALTA, 6.4% of patients experienced pulmonary adverse reactions of any grade, including ILD/pneumonitis, pneumonia and dyspnoea, early in treatment (within 9&nbsp;days, median onset: 2&nbsp;days); 2.7% of patients had Grade&nbsp;3‑4 pulmonary adverse reactions and 1&nbsp;patient (0.5%) had fatal pneumonia. Following Grade&nbsp;1‑2 pulmonary adverse reactions, treatment with Alunbrig was either interrupted and then restarted or the dose was reduced. Early pulmonary adverse reactions also occurred in a dose escalation study in patients (N&nbsp;=&nbsp;137) (Study 101) including three fatal cases (hypoxia, acute respiratory distress syndrome and pneumonia).</p><p>&nbsp;</p><p>Additionally, 2.3% of patients in ALTA experienced pneumonitis later in treatment, with 2&nbsp;patients having Grade&nbsp;3 pneumonitis (see sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>In ALTA, 13.5% of patients&nbsp;&ge;&nbsp;65&nbsp;years of age experienced an early pulmonary adverse reaction compared with 4.2% of patients&nbsp;&lt;&nbsp;65&nbsp;years of age.</p><p>&nbsp;</p><p><em><u>Hypertension</u></em></p><p>In ALTA, hypertension was reported in 28% of patients treated with Alunbrig at the 180&nbsp;mg regimen with 10% having Grade&nbsp;3 hypertension. Dose reduction for hypertension occurred in 0.9% at the 180&nbsp;mg regimen. Mean systolic and diastolic blood pressure, in all patients, increased over time (see sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Bradycardia</u></em></p><p>In ALTA, bradycardia was reported in 4.5% of patients treated with Alunbrig at the 180&nbsp;mg regimen.</p><p>&nbsp;</p><p>Heart rates of less than 50 beats per minute (bpm) were reported in 8.2% of patients at the 180&nbsp;mg regimen. (see sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Visual disturbance</u></em></p><p>In ALTA, visual disturbance adverse reactions were reported in 18% of patients treated with Alunbrig&nbsp;at the 180&nbsp;mg regimen. Of these, three Grade&nbsp;3 adverse reactions (2.7%) including macular oedema and cataract were reported.</p><p>&nbsp;</p><p>Dose reduction for visual disturbance occurred in two patients (1.8%) at the 180&nbsp;mg regimen (see sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Peripheral neuropathy</u></em></p><p>In ALTA, peripheral neuropathy adverse reactions were reported in 27.3% of patients treated at the 180&nbsp;mg regimen. Thirty percent of patients had resolution of all peripheral neuropathy adverse reactions. The median duration of peripheral neuropathy adverse reactions was 4.5&nbsp;months, with a maximum duration of 28.7&nbsp;months.</p><p>&nbsp;</p><p><em><u>Creatine phosphokinase (CPK) elevation</u></em></p><p>In ALTA, elevations of CPK were reported in 50% of patients treated with Alunbrig at the 180&nbsp;mg regimen. The incidence of Grade&nbsp;3‑4 elevations of CPK was 13.6%. The median time to onset for CPK elevations was 27&nbsp;days.</p><p>&nbsp;</p><p>Dose reduction for CPK elevation occurred in 6.4% patients at the 180&nbsp;mg regimen (see sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Elevations of pancreatic enzymes</u></em></p><p>In ALTA, elevations of amylase and lipase were reported in 43% and 50% of patients treated with Alunbrig, respectively at the 180&nbsp;mg regimen. For elevations to Grade&nbsp;3&nbsp;and&nbsp;4, the incidences for amylase and lipase were 8.2% and 10%, respectively. The median time to onset for amylase elevations and lipase elevations was 17&nbsp;days and 29&nbsp;days, respectively.</p><p>&nbsp;</p><p>Dose reduction for elevation of lipase and amylase occurred in 1.8% and 0.9% of patients, respectively at the 180&nbsp;mg regimen (see sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Elevation of hepatic enzymes</u></em></p><p>In ALTA, elevations of ALT and AST were reported in 46% and 65% of patients treated with Alunbrig, respectively at the 180&nbsp;mg regimen. For elevations to Grade&nbsp;3 and 4, the incidences for ALT and AST were 5.5% and 3.6%, respectively.</p><p>&nbsp;</p><p>No patients had dose reductions due to elevation of ALT or AST.</p><p>&nbsp;</p><p><em><u>Hyperglycaemia</u></em></p><p>In ALTA, 69% of patients experienced hyperglycaemia. Grade&nbsp;3 hyperglycemia occurred in 7.3% of patients.</p><p>&nbsp;</p><p>No patients had dose reductions due to hyperglycaemia.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national pharmacovigilance &nbsp;and drug safety center (NPC)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</li><li>Toll free phone: 8002490000</li><li>Reporting hotline: 19999</li></ul><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote for overdose with Alunbrig. In the event of an overdose, monitor the patient for adverse reactions (see section&nbsp;4.8) and provide appropriate supportive care.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitors, ATC code: L01XE43</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Brigatinib is a tyrosine kinase inhibitor that targets ALK, c‑ros oncogene 1 (ROS1), and insulin‑like growth factor 1 receptor (IGF‑1R). Brigatinib inhibited autophosphorylation of ALK and ALK‑mediated phosphorylation of the downstream signalling protein STAT3 in <em>in vitro</em> and <em>in vivo</em> assays.</p><p>&nbsp;</p><p>Brigatinib inhibited the<em> in vitro</em> proliferation of cell lines expressing EML4‑ALK and NPM‑ALK fusion proteins and demonstrated dose‑dependent inhibition of EML4‑ALK‑positive NSCLC xenograft growth in mice. Brigatinib inhibited the <em>in vitro</em> and <em>in vivo</em> viability of cells expressing mutant forms of EML4‑ALK associated with resistance to ALK inhibitors, including G1202R and L1196M.</p><p>&nbsp;</p><p><em><u>Cardiac electrophysiology</u></em></p><p>In Study 101, the QT interval prolongation potential of Alunbrig was assessed in 123&nbsp;patients with advanced malignancies following once daily brigatinib doses of 30&nbsp;mg to 240&nbsp;mg. The maximum mean QTcF (corrected QT by the Fridericia method) change from baseline was less than 10&nbsp;msec. An exposure‑QT analysis suggested no concentration‑dependent QTc interval prolongation.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em><u>ALTA</u></em></p><p>The safety and efficacy of Alunbrig was evaluated in a randomised (1:1), open‑label, multicenter trial (ALTA) in 222&nbsp;adult&nbsp;patients with locally advanced or metastatic ALK‑positive NSCLC who had progressed on crizotinib. Eligibility criteria permitted enrolment of patients with a documented ALK rearrangement based on a validated test, ECOG Performance Status of 0‑2, and prior chemotherapy. Additionally, patients with central nervous system (CNS) metastases were included, provided they were neurologically stable and did not require an increasing dose of corticosteroids. Patients with a history of pulmonary interstitial disease or drug‑related pneumonitis were excluded.</p><p>&nbsp;</p><p>Patients were randomised in a 1:1 ratio to receive Alunbrig either 90&nbsp;mg once daily (90&nbsp;mg regimen, N&nbsp;=&nbsp;112) or 180&nbsp;mg once daily with 7‑day lead‑in at 90&nbsp;mg once daily (180&nbsp;mg regimen, N&nbsp;=&nbsp;110). The median duration of follow‑up was 22.9&nbsp;months. Randomisation was stratified by brain metastases (present, absent) and best prior response to crizotinib therapy (complete or partial response, any other response/unknown).</p><p>&nbsp;</p><p>The major outcome measure was confirmed objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST v1.1) as evaluated by investigator. Additional outcome measures included confirmed ORR as evaluated by an Independent Review Committee (IRC); time to response; progression free survival (PFS); duration of response (DOR); overall survival; and intracranial ORR and intracranial DOR as evaluated by an IRC.</p><p>&nbsp;</p><p>Baseline demographics and disease characteristics in ALTA were median age 54&nbsp;years old (range&nbsp;18&nbsp;to&nbsp;82; 23%&nbsp;65&nbsp;and&nbsp;over), 67%&nbsp;White and 31%&nbsp;Asian, 57%&nbsp;female, 36%&nbsp;ECOG&nbsp;PS&nbsp;0 and 57%&nbsp;ECOG&nbsp;PS&nbsp;1, 7% ECOG PS2, 60% never smoker, 35% former smoker, 5% current smoker, 98%&nbsp;Stage&nbsp;IV, 97%&nbsp;adenocarcinoma, and 74%&nbsp;prior&nbsp;chemotherapy. The most common sites of extra‑thoracic metastasis included 69%&nbsp;brain (of whom 62% had received prior radiation to the brain), 39%&nbsp;bone, and 26%&nbsp;liver.</p><p>&nbsp;</p><p>Efficacy results from ALTA analysis are summarised in Table&nbsp;4. and the Kaplan‑Meier (KM) curve for investigator‑assessed PFS is shown in Figure&nbsp;1.</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Efficacy results in ALTA (ITT population)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Efficacy parameter</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Investigator assessment</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>IRC assessment</strong></p></td></tr><tr><td><p><strong>90&nbsp;mg regimen<sup>*</sup><br />N&nbsp;=&nbsp;112</strong></p></td><td><p><strong>180&nbsp;mg regimen</strong><sup>&dagger;</sup><br /><strong>N&nbsp;=&nbsp;110</strong></p></td><td><p><strong>90&nbsp;mg regimen<sup>*</sup><br />N&nbsp;=&nbsp;112</strong></p></td><td><p><strong>180&nbsp;mg regimen</strong><sup>&dagger;</sup><br /><strong>N&nbsp;=&nbsp;110</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Objective response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>(%)</p></td><td style="vertical-align:top"><p>46%</p></td><td style="vertical-align:top"><p>56%</p></td><td style="vertical-align:top"><p>51%</p></td><td style="vertical-align:top"><p>56%</p></td></tr><tr><td style="vertical-align:top"><p>CI<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>(35, 57)</p></td><td style="vertical-align:top"><p>(45, 67)</p></td><td style="vertical-align:top"><p>(41, 61)</p></td><td style="vertical-align:top"><p>(47, 66)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Time to response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months)</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>1.9</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Duration of response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months)</p></td><td style="vertical-align:top"><p>12.0</p></td><td style="vertical-align:top"><p>13.8</p></td><td style="vertical-align:top"><p>16.4</p></td><td style="vertical-align:top"><p>15.7</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(9.2,17.7)</p></td><td style="vertical-align:top"><p>(10.2,19.3)</p></td><td style="vertical-align:top"><p>(7.4, 24.9)</p></td><td style="vertical-align:top"><p>(12.8, 21.8)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Progression‑free survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months)</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>15.6</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>16.7</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(7.4, 11.1)</p></td><td style="vertical-align:top"><p>(11.1, 21)</p></td><td style="vertical-align:top"><p>(7.4, 12.8)</p></td><td style="vertical-align:top"><p>(11.6, 21.4)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Overall survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months)</p></td><td style="vertical-align:top"><p>29.5</p></td><td style="vertical-align:top"><p>34.1</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(18.2, NE)</p></td><td style="vertical-align:top"><p>(27.7, NE)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>12‑month survival probability (%)</p></td><td style="vertical-align:top"><p>70.3%</p></td><td style="vertical-align:top"><p>80.1%</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr></tbody></table><p>CI&nbsp;=&nbsp;Confidence Interval; NE&nbsp;=&nbsp;Not Estimable; NA&nbsp;=&nbsp;Not Applicable</p><p>*90&nbsp;mg once daily regimen</p><p><sup>&dagger;</sup>180&nbsp;mg once daily with 7‑day lead‑in at 90&nbsp;mg once daily<sup> </sup></p><p><sup>&Dagger;</sup>Confidence Interval for investigator assessed ORR is 97.5% and for IRC assessed ORR is 95%</p><p>&nbsp;</p><p>breviations: ITT&nbsp;=&nbsp;Intent‑to‑treat</p><p>Note: Progression‑Free survival was defined as time from initiation of treatment until the date at which disease progression was first evident or death, whichever comes first.</p><p>*90&nbsp;mg once daily regimen</p><p><sup>&dagger;</sup>180&nbsp;mg once daily with 7‑day lead‑in at 90&nbsp;mg once daily<sup> </sup></p><p>&nbsp;</p><p>IRC assessments of intracranial ORR and duration of intracranial response in patients from ALTA with measurable brain metastases (&ge;&nbsp;10&nbsp;mm in longest diameter) at baseline are summarised in Table&nbsp;5.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;5: Intracranial efficacy in patients with measurable brain metastases at baseline in ALTA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2"><p><strong>IRC-assessed efficacy parameter</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Patients with measurable brain metastases at baseline</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>90&nbsp;mg regimen</strong>*<br /><strong>(N&nbsp;=&nbsp;26)</strong></p></td><td style="vertical-align:top"><p><strong>180&nbsp;mg regimen</strong><sup>&dagger;</sup><br /><strong>(N&nbsp;=&nbsp;18)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Intracranial objective response rate </strong></p></td></tr><tr><td style="vertical-align:bottom"><p>(%)</p></td><td style="vertical-align:top"><p>50%</p></td><td style="vertical-align:top"><p>67%</p></td></tr><tr><td style="vertical-align:bottom"><p>95% CI</p></td><td style="vertical-align:top"><p>(30, 70)</p></td><td style="vertical-align:top"><p>(41, 87)</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Intracranial disease control rate </strong></p></td></tr><tr><td style="vertical-align:bottom"><p>(%)</p></td><td style="vertical-align:top"><p>85%</p></td><td style="vertical-align:top"><p>83%</p></td></tr><tr><td style="vertical-align:bottom"><p>95% CI</p></td><td style="vertical-align:top"><p>(65, 96)</p></td><td style="vertical-align:top"><p>(59, 96)</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Duration of </strong><strong>intracranial response<sup>&Dagger;</sup>,</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Median (months)</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>16.6</p></td></tr><tr><td style="vertical-align:bottom"><p>95% CI</p></td><td style="vertical-align:top"><p>(3.7, 24.9)</p></td><td style="vertical-align:top"><p>(3.7, NE)</p></td></tr></tbody></table><p>%&nbsp;CI&nbsp;=&nbsp;Confidence Interval; NE&nbsp;=&nbsp;Not Estimable</p><p>*90&nbsp;mg once daily regimen</p><p><sup>&dagger;</sup>180&nbsp;mg once daily with 7‑day lead‑in at 90&nbsp;mg once daily<sup> </sup></p><p><sup>&Dagger;</sup>Events include intracranial disease progression (new lesions, intracranial target lesion diameter growth &ge;&nbsp;20% from nadir, or unequivocal progression of intracranial non‑target lesions) or death.</p><p>&nbsp;</p><p>In patients with any brain metastases at baseline, intracranial disease control rate was 77.8% (95% CI 67.2‑86.3) in the 90&nbsp;mg arm (N&nbsp;=&nbsp;81) and 85.1% (95% CI 75‑92.3) in the 180&nbsp;mg arm (N=74).</p><p>&nbsp;</p><p><em><u>Study 101</u></em></p><p>In a separate dose finding study, 25&nbsp;patients with ALK‑positive NSCLC that progressed on crizotinib were administered Alunbrig at 180&nbsp;mg once daily with 7‑day lead‑in at 90&nbsp;mg once daily regimen. Of these, 19 patients had an investigator‑assessed confirmed objective response (76%; 95% CI: 55, 91) and the KM estimate median duration of response among the 19&nbsp;responders was 26.1&nbsp;months (95% CI: 7.9, 26.1). The KM median PFS was 16.3&nbsp;months (95% CI: 9.2, NE) and the 12‑month probability of overall survival was 84.0% (95% CI: 62.8, 93.7).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Alunbrig in all subsets of the paediatric population in lung carcinoma (small cell and non‑small cell carcinoma) (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>In Study&nbsp;101, following administration of a single oral dose of brigatinib (30‑240&nbsp;mg) in patients, the median time to peak concentration (T<sub>max</sub>) was 1‑4&nbsp;hours postdose. After a single dose and at steady state, systemic exposure was dose proportional over the dose range of 60‑240&nbsp;mg once daily. Modest accumulation was observed upon repeated dosing (geometric mean accumulation ratio:&nbsp;1.9&nbsp;to&nbsp;2.4). The geometric mean steady state C<sub>max</sub> of brigatinib at doses of 90&nbsp;mg and 180&nbsp;mg once daily was 552 and 1,452&nbsp;ng/mL, respectively, and the corresponding AUC<sub>0‑</sub><sub>t</sub> was 8,165 and 20,276&nbsp;h∙ng/mL, respectively. Brigatinib is a substrate of the transporter proteins P‑gp and BCRP.</p><p>&nbsp;</p><p>In healthy subjects, compared to overnight fasting, a high fat meal reduced brigatinib C<sub>max</sub> by 13% with no effect on AUC. Brigatinib can be administered with or without food.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>Brigatinib was moderately bound (91%) to human plasma proteins and binding was not concentration‑dependent. The blood‑to‑plasma concentration ratio is 0.69. In patients given brigatinib 180&nbsp;mg once daily, the geometric mean apparent volume of distribution (V<sub>z/</sub>F) of brigatinib at steady state was 153&nbsp;L, indicating moderate distribution into tissues.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p><em>In vitro</em> studies demonstrated that brigatinib is primarily metabolised by CYP2C8 and CYP3A4, and to a much lesser extent by CYP3A5.</p><p>&nbsp;</p><p>Following oral administration of a single 180&nbsp;mg dose of [<sup>14</sup>C]brigatinib to healthy subjects, N‑demethylation and cysteine conjugation were the two major metabolic clearance pathways. In urine and faeces combined, 48%, 27%, and 9.1% of the radioactive dose was excreted as unchanged brigatinib, N‑desmethyl brigatinib (AP26123), and brigatinib cysteine conjugate, respectively. Unchanged brigatinib was the major circulating radioactive component (92%) along with AP26123 (3.5%), the primary metabolite also observed <em>in vitro</em>. In patients, at steady state, the plasma AUC of AP26123 was&nbsp;&lt;&nbsp;10% of brigatinib exposure. In <em>in vitro</em> kinase and cellular assays, the metabolite, AP26123, inhibited ALK with approximately 3‑fold lower potency than brigatinib.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>In patients given brigatinib 180&nbsp;mg once daily, the geometric mean apparent oral clearance (CL/F) of brigatinib at steady state was 13&nbsp;L/h and the median plasma elimination half‑life was 24&nbsp;h.</p><p>&nbsp;</p><p>The primary route of excretion of brigatinib is in faeces. In six healthy male subjects given a single 180&nbsp;mg oral dose of [<sup>14</sup>C]brigatinib, 65% of the administered dose was recovered in faeces and 25% of the administered dose was recovered in urine. Unchanged brigatinib represented 41% and 86% of the total radioactivity in faeces and urine, respectively, the remainder being metabolites.</p><p><u>&nbsp;</u></p><p><u>Specific populations</u></p><p><em>&nbsp;</em></p><p><em><u>Hepatic impairment</u></em></p><p>The pharmacokinetics of brigatinib was characterised in healthy subjects with normal hepatic function (N&nbsp;=&nbsp;9), and patients with mild hepatic impairment (Child‑Pugh class A, N&nbsp;=&nbsp;6), moderate hepatic impairment (Child‑Pugh class B, N&nbsp;=&nbsp;6), or severe hepatic impairment (Child‑Pugh class C, N&nbsp;=&nbsp;6). The pharmacokinetics of brigatinib was similar between healthy subjects with normal hepatic function and patients with mild (Child‑Pugh class A) or moderate (Child‑Pugh class B) hepatic impairment. Unbound AUC<sub>0‑INF </sub>was 37% higher in patients with severe hepatic impairment (Child‑Pugh class C) as compared to healthy subjects with normal hepatic function (see section&nbsp;4.2).</p><p><em>&nbsp;</em></p><p><em><u>Renal impairment</u></em></p><p>The pharmacokinetics of brigatinib is similar in patients with normal renal function and in patients with mild or moderate renal impairment (eGFR&nbsp;&ge;&nbsp;30&nbsp;mL/min) based on the results of population pharmacokinetic analyses. In a pharmacokinetic study, unbound AUC<sub>0‑INF </sub>was 94% higher in patients with severe renal impairment (eGFR&nbsp;&lt;&nbsp;30&nbsp;mL/min, N&nbsp;=&nbsp;6) as compared to patients with normal renal function (eGFR&nbsp;&ge;&nbsp;90&nbsp;mL/min, N&nbsp;=&nbsp;8) (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Race and gender</u></em></p><p>Population pharmacokinetic analyses showed that race and gender had no impact on the pharmacokinetics of brigatinib.</p><p><em>&nbsp;</em></p><p><em><u>Age, body weight, and albumin concentrations</u></em></p><p>The population pharmacokinetic analyses showed that body weight, age, and albumin concentration had no clinically relevant impact on the pharmacokinetics of brigatinib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety pharmacology studies with brigatinib identified potential for pulmonary effects (altered respiration rate; 1‑2&nbsp;times the human C<sub>max</sub>), cardiovascular effects (altered heart rate and blood pressure; at 0.5&nbsp;times the human C<sub>max</sub>), and renal effects (reduced renal function; at 1‑2.5&nbsp;times the human C<sub>max</sub>), but did not indicate any potential for QT prolongation or neurofunctional effects.</p><p>&nbsp;</p><p>Adverse reactions seen in animals at exposure levels similar to clinical exposure levels with possible relevance to clinical use were as follows: gastrointestinal system, bone marrow, eyes, testes, liver, kidney, bone, and heart. These effects were generally reversible during the non‑dosing recovery period; however, effects in the eyes and testes were notable exceptions due to lack of recovery.</p><p>In repeated dose toxicity studies, lung changes (foamy alveolar macrophages) were noted in monkeys at &ge;&nbsp;0.2&nbsp;times the human AUC; however, these were minimal and similar to those reported as background findings in naive monkeys, and there was no clinical evidence of respiratory distress in these monkeys.</p><p>&nbsp;</p><p>Carcinogenicity studies have not been performed with brigatinib.</p><p>&nbsp;</p><p>Brigatinib was not mutagenic <em>in vitro</em> in the bacterial reverse mutation (Ames) or the mammalian cell chromosomal aberration assays, but slightly increased the number of micronuclei in a rat bone marrow micronucleus test. The mechanism of micronucleus induction was abnormal chromosome segregation (aneugenicity) and not a clastogenic effect on chromosomes. This effect was observed at approximately five fold the human exposure at the 180&nbsp;mg once daily dose.</p><p>&nbsp;</p><p>Brigatinib may impair male fertility. Testicular toxicity was observed in repeat‑dose animal studies. In rats, findings included lower weight of testes, seminal vesicles and prostate gland, and testicular tubular degeneration; these effects were not reversible during the recovery period. In monkeys, findings included reduced size of testes along with microscopic evidence of hypospermatogenesis; these effects were reversible during the recovery period. Overall, these effects on the male reproductive organs in rats and monkeys occurred at exposures &ge;&nbsp;0.2‑times the AUC observed in patients at the 180&nbsp;mg once daily dose. No apparent adverse effects on female reproductive organs were observed in general toxicology studies in rats and monkeys.</p><p>&nbsp;</p><p>In an embryo‑foetal development study in which pregnant rats were administered daily doses of brigatinib during organogenesis; dose‑related skeletal anomalies were observed at doses as low as approximately 0.7‑times the human exposure by AUC at the 180&nbsp;mg once daily dose. Findings included embryo‑lethality, reduced foetal growth, and skeletal variations.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Lactose monohydrate</p><p>Microcrystalline cellulose</p><p>Sodium starch glycolate (type A)</p><p>Silica colloidal hydrophobic</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Tablet coating</u></p><p>Talc</p><p>Macrogol</p><p>Polyvinyl alcohol</p><p>Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C,</p><p>Store in the original container, Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Alunbrig 30&nbsp;mg film‑coated tablets</u></p><p>Clear thermoformable poly‑chloro‑tri‑fluoro‑ethylene (PCTFE) blister with heat sealable paper‑laminated foil lidding in a carton, containing either 28, 56&nbsp;or 112&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p><u>Alunbrig 90&nbsp;mg film‑coated tablets</u></p><p>Clear thermoformable poly‑chloro‑tri‑fluoro‑ethylene (PCTFE) blister with heat sealable paper‑laminated foil lidding in a carton, containing either 7&nbsp;or 28&nbsp;film‑coated tablets.</p><p><u>&nbsp;</u></p><p><u>Alunbrig 180&nbsp;mg film‑coated tablets</u></p><p>Clear thermoformable poly‑chloro‑tri‑fluoro‑ethylene (PCTFE) blister with heat sealable paper‑laminated foil lidding in a carton, containing 28&nbsp;film‑coated tablets.</p><p><u>&nbsp;</u></p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised to keep the desiccant canister in the bottle and not to swallow it.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements<u> </u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Takeda Pharma A/S
	Dybendal Alle 10
	2630 Taastrup
	Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This SPC is last revised in January 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>